[ CAS No. 16665-38-6 ] {[proInfo.proName]}

Name: 16665-38-6|(4-Methoxypyridin-2-yl)methanol|95%
Brand: Ambeed
SKU: A119923
Price: 6.0 USD
Availability: InStock
Rating: 98 (27 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 16665-38-6

Structure of 16665-38-6 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 16665-38-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 16665-38-6 ]

SDS Specification

Alternatived Products of [ 16665-38-6 ]

Product Details of [ 16665-38-6 ]

CAS No. :	16665-38-6	MDL No. :	MFCD07774100
Formula :	C₇H₉NO₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	GBMRUSRMPOUVEK-UHFFFAOYSA-N
M.W :	139.15	Pubchem ID :	10820596
Synonyms :

Calculated chemistry of [ 16665-38-6 ]

Physicochemical Properties

Num. heavy atoms :	10
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.29
Num. rotatable bonds :	2
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	36.86
TPSA :	42.35 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.17 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.51
Log Po/w (XLOGP3) :	-0.03
Log Po/w (WLOGP) :	0.43
Log Po/w (MLOGP) :	-0.39
Log Po/w (SILICOS-IT) :	1.17
Consensus Log Po/w :	0.54

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.0
Solubility :	14.0 mg/ml ; 0.101 mol/l
Class :	Very soluble
Log S (Ali) :	-0.41
Solubility :	54.2 mg/ml ; 0.39 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-1.95
Solubility :	1.55 mg/ml ; 0.0111 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.54

Safety of [ 16665-38-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 16665-38-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 16665-38-6 ]
Downstream synthetic route of [ 16665-38-6 ]

[ 16665-38-6 ] Synthesis Path-Upstream 1~2

1
[ 16665-38-6 ]
[ 16744-81-3 ]

Yield	Reaction Conditions	Operation in experiment
62.9%	With manganese(IV) oxide In ethyl acetate at 80℃; for 2 h;	4-Methoxypyridine-2-carbaldehyde, used as starting material was prepared as follows:- Manganese(IV) oxide (2.412 mL, 139.42 mmol, 4eq) was added portionwise to (4- methoxypyridin-2-yl)methanol (4.85g, 34.85 mmol, leq) in ethyl acetate (15OmL). The resulting mixture was stirred at 80 ⁰C for 2 h. The hot reaction mixture was filtered through celite. The resulting mixture was evaporated to dryness to afford desired A- methoxypyridine-2-carbaldehyde (3.01 g, 21.93 mmol, 62.9 percent). IH NMR (400.132 MHz, DMSO) δ 3.93 (3H, s), 7.27 (IH, m), 7.44 (IH, d), 8.63 (IH, d), 9.96 (IH, s)
46%	With manganese(IV) oxide In chloroform for 2.5 h; Reflux	A suspension of 17 (420 mg, 3.02 mmol) and MnO₂ (3.2 g) in dry CHCl₃ (5 mL) was refluxed for 2.5 hr. After removal of MnO₂ by filtration, the filtrate was concentrated under reduced pressure to give 18 (193 mg, 46 percent) as a pale yellow solid.
193 mg	With manganese(IV) oxide In ethyl acetate for 3 h; Reflux	Manganese dioxide (696 mg) was added to a solution of (4-methoxypyridin-2-yl)methanol (278 mg) obtained in Reference Example 21-6 (3) in ethyl acetate (5 mL), followed by refluxing for 1 hour. Manganese dioxide (696 mg) was added thereto, followed by refluxing for 2 hours. The reaction mixture was cooled to room temperature, the insoluble materials were filtered off, and the solvent was distilled off under reduced pressure. The obtained residues were purified by silica gel column chromatography (ethyl acetate), whereby 4-methoxypicolinic aldehyde (193 mg) was obtained as a colorless oily material

Reference： [1] Patent: WO2009/56886, 2009, A1, . Location in patent: Page/Page column 54
[2] Chemical and Pharmaceutical Bulletin, 1990, vol. 38, # 9, p. 2446 - 2458
[3] Inorganic Chemistry, 2013, vol. 52, # 11, p. 6481 - 6501
[4] Bulletin of the Chemical Society of Japan, 2015, vol. 88, # 6, p. 784 - 791
[5] Yakugaku Zasshi, 1957, vol. 77, p. 11,13[6] Chem.Abstr., 1957, p. 8745
[7] Inorganic Chemistry, 2015, vol. 54, # 21, p. 10141 - 10152
[8] Patent: US2016/168139, 2016, A1, . Location in patent: Paragraph 0970; 0981; 0982

2
[ 16665-38-6 ]
[ 62734-08-1 ]

Reference： [1] Journal of Medicinal Chemistry, 1995, vol. 38, # 25, p. 4906 - 4916
[2] Journal of Medicinal Chemistry, 1992, vol. 35, # 6, p. 1049 - 1057
[3] Patent: US4560693, 1985, A,
[4] Patent: US4562197, 1985, A,
[5] Journal of Organic Chemistry, 2013, vol. 78, # 22, p. 11508 - 11512
[6] Patent: US4083983, 1978, A,

[ 16665-38-6 ] Synthesis Path-Downstream 1~83

1
[ 16665-38-6 ]
[ 16744-81-3 ]

Yield	Reaction Conditions	Operation in experiment
62.9%	With manganese(IV) oxide; In ethyl acetate; at 80℃; for 2h;	4-Methoxypyridine-2-carbaldehyde, used as starting material was prepared as follows:- Manganese(IV) oxide (2.412 mL, 139.42 mmol, 4eq) was added portionwise to (4- methoxypyridin-2-yl)methanol (4.85g, 34.85 mmol, leq) in ethyl acetate (15OmL). The resulting mixture was stirred at 80 0C for 2 h. The hot reaction mixture was filtered through celite. The resulting mixture was evaporated to dryness to afford desired A- methoxypyridine-2-carbaldehyde (3.01 g, 21.93 mmol, 62.9 percent). IH NMR (400.132 MHz, DMSO) delta 3.93 (3H, s), 7.27 (IH, m), 7.44 (IH, d), 8.63 (IH, d), 9.96 (IH, s)
46%	With manganese(IV) oxide; In chloroform; for 2.5h;Reflux;	A suspension of 17 (420 mg, 3.02 mmol) and MnO2 (3.2 g) in dry CHCl3 (5 mL) was refluxed for 2.5 hr. After removal of MnO2 by filtration, the filtrate was concentrated under reduced pressure to give 18 (193 mg, 46 percent) as a pale yellow solid.
193 mg	With manganese(IV) oxide; In ethyl acetate; for 3h;Reflux;	Manganese dioxide (696 mg) was added to a solution of <strong>[16665-38-6](4-methoxypyridin-2-yl)methanol</strong> (278 mg) obtained in Reference Example 21-6 (3) in ethyl acetate (5 mL), followed by refluxing for 1 hour. Manganese dioxide (696 mg) was added thereto, followed by refluxing for 2 hours. The reaction mixture was cooled to room temperature, the insoluble materials were filtered off, and the solvent was distilled off under reduced pressure. The obtained residues were purified by silica gel column chromatography (ethyl acetate), whereby 4-methoxypicolinic aldehyde (193 mg) was obtained as a colorless oily material

Reference： [1]Patent: WO2009/56886,2009,A1 .Location in patent: Page/Page column 54
[2]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458
[3]Inorganic Chemistry,2013,vol. 52,p. 6481 - 6501
[4]Bulletin of the Chemical Society of Japan,2015,vol. 88,p. 784 - 791
[5]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1957,vol. 77,p. 11,13
Chem.Abstr.,1957,p. 8745
[6]Inorganic Chemistry,2015,vol. 54,p. 10141 - 10152
[7]Patent: US2016/168139,2016,A1 .Location in patent: Paragraph 0970; 0981; 0982

2
[ 6890-60-4 ]
[ 16665-38-6 ]

Yield	Reaction Conditions	Operation in experiment
55.6%		(4-Methoxypyridin-2-yl)methanol, used as starting material was prepared as follows:- Trifiuoroacetic anhydride (50.8 mL, 359.32 mmol, 5eq) was added dropwise to A- methoxy-2-methylpyridine 1-oxide (1Og, 71.86 mmol, leq) in DCM (40OmL) at 0 0C over a period of 20 mins under nitrogen. The resulting solution was stirred at room temperature for 30 mins. The temperature was increased to 40 0C and the reaction mixture was stirred for a further 6 h then left to stir at room temperature overnight. The reaction mixture was quenched carefully with saturated sodium bicarbonate and stirred for 1 h. The reaction mixture was extracted with DCM and the organic layers were combined and washed with brine, dried (MgSO4), filtered and evaporated under reduced pressure to give (4- methoxypyridin-2-yl)methanol (5.56 g, 39.94mmol, 55.6 %) as a yellow oil. IH NMR (400.132 MHz, DMSO) delta 3.83 (3H, s), 4.52 (2H, s), 5.38 (IH, s), 6.82 (IH, m), 7.01 (IH, d), 8.29 (IH, d)

Reference： [1]Patent: WO2009/56886,2009,A1 .Location in patent: Page/Page column 54
[2]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1957,vol. 77,p. 11,13
Chem.Abstr.,1957,p. 8745
[3]Journal of the American Chemical Society,2003,vol. 125,p. 5186 - 5192
[4]Chemical and Pharmaceutical Bulletin,2000,vol. 48,p. 1514 - 1518
[5]Journal of Medicinal Chemistry,1998,vol. 41,p. 1777 - 1788
[6]Journal of Medicinal Chemistry,1995,vol. 38,p. 4906 - 4916
[7]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057
[8]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450
[9]Journal of Organic Chemistry,2013,vol. 78,p. 11508 - 11512
[10]Patent: US2016/168139,2016,A1
[11]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824

3
[ 6890-60-4 ]
[ 16665-38-6 ]
[ 102074-64-6 ]

Reference： [1]Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan,1957,vol. 77,p. 11,13
Chem.Abstr.,1957,p. 8745

4
[ 186581-53-3 ]
[ 82153-31-9 ]
[ 16665-38-6 ]

Reference： [1]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458

5
[ 67-56-1 ]
1,4-dimethoxypyridin-1-ium tetrafluoroborate [ No CAS ]
[ 16665-38-6 ]

Reference： [1]Synthetic Communications,1989,vol. 19,p. 317 - 326

6
[ 16665-38-6 ]
[ 99651-28-2 ]

Yield	Reaction Conditions	Operation in experiment
100%	With thionyl chloride; In dichloromethane; at 0 - 45℃; for 3.5h;	To a cooled (0 C) solution of 17 (700 mg, 5.03 mmol) in dry CH2Cl2 (4 mL) was added dropwise SOCl2 (2.2 mL, 30.8 mmol). The reaction mixture was stirred at 45 C for 3.5 hr. After removal of the solvent under reduced pressure, the residue was dissolved in sat. NaHCO3 and extracted with CHCl3. The extracts were dried over MgSO4 and concentrated under reduced pressure to give 19 (796 mg, quant.) as a red liquid.

Reference： [1]Bulletin of the Chemical Society of Japan,2015,vol. 88,p. 784 - 791
[2]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450
[3]Journal of Medicinal Chemistry,1998,vol. 41,p. 1777 - 1788
[4]Chemical and Pharmaceutical Bulletin,2000,vol. 48,p. 1514 - 1518
[5]Journal of the American Chemical Society,2003,vol. 125,p. 5186 - 5192
[6]Journal of Organic Chemistry,2017,vol. 82,p. 8686 - 8696

7
[ 16665-38-6 ]
[ 62734-08-1 ]

Yield	Reaction Conditions	Operation in experiment
	With thionyl chloride; In chloroform;	14. 2-Chloromethyl-4-methoxypyridine hydrochloride 15 ml of thionyl chloride are added dropwise to a solution, cooled to -10 C., of 10 g (0.072 mole) of <strong>[16665-38-6]2-hydroxymethyl-4-methoxypyridine</strong> in 30 ml of dry chloroform in the course of 15 minutes. The solution is allowed to come to room temperature and stirring is continued for one and a half hours. After the solvent and the excess thionyl chloride have been stripped off, colorless crystals are obtained, and these are recrystallized from isopropanol [12.1 g (87%), m.p. 149-150 C., decomposition].
	With thionyl chloride;	(4) 2-Chloromethyl-4-methoxypyridine hydrochloride This was prepared by the method of Baker et. al., J. Chem. Soc., Chem. Comm., 3598, 1958, but starting with <strong>[16665-38-6]2-hydroxymethyl-4-methoxypyridine</strong> (as prepared in (3) above, 44.05 g, 0.317 mole) and thionyl chloride (500 ml) to give the title compound as a reddish solid, 46 g (75%) which was used directly in the following preparation without further purification.
	With thionyl chloride; In chloroform;	(1) Thionyl chloride (23 cc) was added over 25 minutes to a stirred solution of <strong>[16665-38-6]2-hydroxymethyl-4-methoxypyridine</strong> (8.935 g) in chloroform at room temperature, and the mixture was stirred for a further 2 hours and was evaporated to dryness and the residue was triturated with ether and recrystallized from 0.9N ethanolic hydrogen chloride/ether (7:5) to give 2-chloromethyl-4-methoxypyridine hydrochloride m.p. 142 (decomp).(12.1 g).

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4906 - 4916
[2]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057
[3]Patent: US4560693,1985,A
[4]Patent: US4562197,1985,A
[5]Journal of Organic Chemistry,2013,vol. 78,p. 11508 - 11512
[6]Patent: US4083983,1978,A

8
[ 16665-37-5 ]
[ 16665-38-6 ]

Yield	Reaction Conditions	Operation in experiment
67%	With potassium carbonate; In hydrogenchloride;	(3) 2-Hydroxymethyl-4-methoxypyridine A solution of 2-acetoxymethyl-4-methoxypyridine (20.72 g, 0.114 mole) in 3M hydrochloric acid (100 ml) was heated under reflux for 1 hour. The resulting solution was concentrated under reduced pressure and the residue neutralised by addition of potassium carbonate. The mixture was extracted with dichloromethane and the organic solution dried over anhydrous sodium sulphate, filtered and evaporated to give a light coloured viscous oil which solidified on standing to yield the title compound (10.6 g, 67%) b.p. 135 C. at 0.1 mm mercury.
820 mg	With sodium hydroxide; In methanol; water; for 3h;Reflux;	Methanol (5 mL) and a 2 mol/L sodium hydroxide aqueous solution (5 mL) were added to (4-methoxypyridin-2-yl)methyl acetate obtained in Reference Example 21-6 (2), followed by refluxing for 3 hours. The reaction mixture was cooled to room temperature, 2 mol/L hydrochloric acid was added thereto, the resultant product was extracted with chloroform and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residues were purified by silica gel column chromatography (ethyl acetate:methanol=1:0?9:1), whereby (4-methoxypyridin-2-yl)methanol (820 mg) was obtained as a white solid. (0979) MS(ESI m/z): 140 (M+H) (0980) RT(min): 0.25

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824
[2]Patent: US4562197,1985,A
[3]Tetrahedron Asymmetry,2009,vol. 20,p. 1672 - 1682
[4]Journal of Medicinal Chemistry,1998,vol. 41,p. 1777 - 1788
[5]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057
[6]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450
[7]Journal of Medicinal Chemistry,1995,vol. 38,p. 4906 - 4916
[8]Chemical and Pharmaceutical Bulletin,2000,vol. 48,p. 1514 - 1518
[9]Patent: US2016/168139,2016,A1 .Location in patent: Paragraph 0970; 0977-0980

9
[ 87838-47-9 ]
[ 16665-38-6 ]

Reference： [1]Journal of Chemical Research, Miniprint,1983,p. 1341 - 1350

Yield	Reaction Conditions	Operation in experiment
		4-Methoxypyrid-2-ylcarbinol was prepared by the method of Katz, et al. and purified by chromatography, eluding with dichloromethane:methanol (95:5); TLC: Rf =0.45, dichloromethane:methanol (9:1); 300 MHz NMR: 3.82 (s,3), 4.50 (d,2), 5.40 (t,1), 6.81 (dd,1), 7.00 (d,1), 8.28 (d,1); MS: m/z=140(M+1). Example 25.b.: Isolated and used without further purification; TLC: Rf =0.25, dichloromethane:methanol (95:5); MS: m/z=563(M+1).
		14. 2-Chloromethyl-4-methoxypyridine hydrochloride 15 ml of thionyl chloride are added dropwise to a solution, cooled to -10 C., of 10 g (0.072 mole) of 2-hydroxymethyl-4-methoxypyridine in 30 ml of dry chloroform in the course of 15 min.. The solution is allowed to come to room temperature and stirring is continued for 1.5 h. After the solvent and the eccess thionyl chloride have been stripped off, colorless crystals are obtained, and these are recrystallized from isopropanol [12.1 g (87%), m.p. 149-150 C., decomposition].
		PREPARATION 25 2-Hydroxymethyl4-methoxypyridine Title product of the preceding Preparation (20.75 g, 0.114 mol) and sodium methoxide (9.23 g, 0.171 mol) were combined in 110 ml methanol and heated under reflux for 65 minutes. The mixture was cooled, stripped in vacuo, the residue taken up in 100 ml H2 O, neutralized with 1N HCl and extracted with 3*70 ml of ethyl acetate. The organic layers were combined, dried (Na2 SO4) and stripped to yield title product as a solid, 14.2 g.

12
[ 16665-38-6 ]
[ 870862-63-8 ]
Phosphoric acid di-tert-butyl ester (R)-3-[4-(4-methoxy-pyridin-2-ylmethoxy)-phenyl]-2-((Z)-octadec-9-enoylamino)-propyl ester [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 4069 - 4074

13
[ 16665-38-6 ]
[ 1000896-60-5 ]

Yield	Reaction Conditions	Operation in experiment
67%		5-[(5-Fluoro-2-methoxy-pyridin-4-yl)methoxy]-1H-pyrazol-3-amine, used as starting material, was prepared as follows:; -3-Amino-5-hydroxypyrazole (0.56 g, 5.65 mmol) and triphenylphosphine (1.78 g, 6.78 mmol) were stirred in DCM (I6 ml) under nitrogen and the reaction mixture was cooled in an ice-bath. Diisopropylazodicarboxylate (1.34 ml, 6.78 mmol) was added dropwise over a period of 10 min. The reaction mixture was then stirred in the ice-bath for 1 h. (5-Fluoro-2-methoxy-pyridin-4-yl)methanol (1.07 g, 6.78 mmol) in THF (15 ml) was added slowly over 5-10 min. The reaction mixture was stirred and allowed to warm to room temperature over 1 h. This was then stirred for a further 18 h. The mixture was filtered and washed through with DCM (10 ml). The filtrate was extracted with 2M HCl(aq) (3×8 ml) and the combined extracts were basified with 6N NaOH(aq). The basified aqueous phase was extracted with DCM (3×20 ml). The combined extracts were filtered, dried over MgSO4, filtered and evaporated. The crude product was purified by silica column chromatography, eluting with 0-3% MeOH in DCM, to afford 5-[(5-fluoro-2-methoxy-pyridin-4-yl)methoxy]-1H-pyrazol-3-amine as a white solid (354 mg, 26% yield).1H NMR (399.902 MHz, DMSO) delta 3.75 (s, 3H), 4.70 (s, 1H), 4.91 (s, 2H), 5.06 (s, 2H), 6.76 (d, 1H), 8.04 (d, 1H), 10.37 (s, 1H); m/z (ES+) [M+H]+=239.

Reference： [1]Patent: US2008/4302,2008,A1 .Location in patent: Page/Page column 106

14
[ 931-19-1 ]
[ 16665-38-6 ]

Reference： [1]Journal of the American Chemical Society,2003,vol. 125,p. 5186 - 5192
[2]Chemical and Pharmaceutical Bulletin,2000,vol. 48,p. 1514 - 1518
[3]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057
[4]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458
[5]Inorganic Chemistry,2013,vol. 52,p. 6481 - 6501
[6]Journal of Organic Chemistry,2013,vol. 78,p. 11508 - 11512
[7]Inorganic Chemistry,2015,vol. 54,p. 10141 - 10152

15
[ 16665-38-6 ]
[ 363625-74-5 ]

Reference： [1]Journal of the American Chemical Society,2003,vol. 125,p. 5186 - 5192

16
[ 5470-66-6 ]
[ 16665-38-6 ]

Reference： [1]Journal of the American Chemical Society,2003,vol. 125,p. 5186 - 5192
[2]Chemical and Pharmaceutical Bulletin,2000,vol. 48,p. 1514 - 1518
[3]Journal of Medicinal Chemistry,1998,vol. 41,p. 1777 - 1788
[4]Journal of Medicinal Chemistry,1995,vol. 38,p. 4906 - 4916
[5]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057
[6]Chemical and Pharmaceutical Bulletin,1990,vol. 38,p. 2446 - 2458
[7]Inorganic Chemistry,2013,vol. 52,p. 6481 - 6501
[8]Journal of Organic Chemistry,2013,vol. 78,p. 11508 - 11512
[9]Inorganic Chemistry,2015,vol. 54,p. 10141 - 10152
[10]Patent: US2016/168139,2016,A1

17
[ 16665-38-6 ]
N,N,N',N'-tetrakis(4-methoxy-2-pyridylmethyl)ethylenediamine [ No CAS ]

Reference： [1]Chemical and Pharmaceutical Bulletin,2000,vol. 48,p. 1514 - 1518

18
[ 16665-38-6 ]
2-(((4-methoxypyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1998,vol. 41,p. 1777 - 1788

19
[ 109-06-8 ]
sulfur [ No CAS ]
[ 16665-38-6 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4906 - 4916

20
[ 16665-38-6 ]
[ 1027185-19-8 ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4906 - 4916

21
[ 16665-38-6 ]
4,6-Difluoro-2-(4-methoxy-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 4906 - 4916

22
[ 16744-81-3 ]
[ 16665-38-6 ]

Reference： [1]Green Chemistry,2017,vol. 19,p. 3296 - 3301
[2]Journal of Chemical Research, Miniprint,1983,p. 1341 - 1350

23
[ 87838-46-8 ]
[ 16665-38-6 ]

Reference： [1]Journal of Chemical Research, Miniprint,1983,p. 1341 - 1350

24
[ 1122-96-9 ]
[ 16665-38-6 ]

Reference： [1]Synthetic Communications,1989,vol. 19,p. 317 - 326

25
[ 16665-38-6 ]
[ 97964-23-3 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057

26
[ 16665-38-6 ]
[ 97966-99-9 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057

27
[ 16665-38-6 ]
[ 97964-04-0 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057

28
[ 16665-38-6 ]
[ 97964-15-3 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057

29
[ 16665-38-6 ]
[ 97966-85-3 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057

30
[ 16665-38-6 ]
[ 97963-96-7 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 1049 - 1057

31
[ 16665-38-6 ]
[ 111371-35-8 ]